Shilpa Medicare arm to infuse USD 2 million in Alveolus Bio

Written by Ruchika Sharma Published On 2025-07-25T12:13:40+05:30 | Updated On 25 July 2025 12:13 PM IST

Shilpa Pharma to infuse USD 2 million in Alveolus Bio

Raichur: Shilpa Medicare has announced that Shilpa Pharma Inc, a wholly owned subsidiary of the company, will make a strategic investment of USD 2 million in Alveolus Bio, a biotech startup based out of USA, advancing inhaled live biotherapeutics and small molecule therapies for chronic and life‐threatening lung diseases.

The investment will be made in the form of SAFE (Simple Agreement for Future Equity) Notes, which will convert into a percentage of shareholding upon fulfilment of certain conditions.

Under this strategic engagement, Shilpa Biologics Private Limited – the biologics arm of Shilpa Medicare – will additionally serve asthe exclusive global development and manufacturing partner for Alveolus Bio.

This collaboration combines Shilpa’s expertise in turnkey biologics development, process optimization, and manufacturing with Alveolus Bio’s cutting‐edge resMIT platform, which engineers inhalable live therapeutics to address hard‐to‐ treat respiratory conditions like COPD, Bronchopulmonary Dysplasia, and Pulmonary Fibrosis.

“Shilpa Medicare has always been at the forefront of enabling breakthrough biologics with our world‐class development and manufacturing capabilities,” said Vishnukant Bhutada, Managing Director, Shilpa Medicare Limited. “This partnership with Alveolus Bio not only strengthens our innovation pipeline but also positions Shilpa as a key global partner for biotech companies looking to translate bold science into scalable clinical and commercial solutions.”

The investment will fund Alveolus Bio’s lead COPD program through Phase 2 clinical trials and accelerate additional preclinical programs. Importantly, the collaboration also creates a platform for co‐development and future manufacturing partnerships.

“This partnership with Shilpa Medicare is not just about funding—it’s about combining deep biotech innovation with proven pharmaceutical execution,” said Gaurav Mehta, CEO of Alveolus Bio. “Together, we can deliver these life‐changing therapies to patients much faster and more efficiently.”

The move aligns with Shilpa’s strategy to expand its biologics footprint, diversify into innovative therapeutic platforms, and build strategic alliances with disruptive biotech companies globally, according to the release.

“The science at Alveolus Bio represents a paradigm shift in respiratory medicine,” added Dr. C. Vivek Lal, Founder and Chief Scientific Officer of Alveolus Bio. “This partnership seamlessly bridges cutting‐ edge biotech innovation with Shilpa’s global pharmaceutical leadership, enabling rapid clinical translation of our novel therapies.”

Alveolus Bio, a company based out of USA is pioneering breakthrough therapeutic assets for lung diseases through its proprietary resMIT platform. The company's pipeline includes preclinical phase live biotherapeutics for Chronic Obstructive Pulmonary Disease (COPD), Bronchopulmonary Dysplasia (BPD), Pulmonary Fibrosis, Lung Injury Secondary to Viral Infection, Neutrophilic Asthma, and earlier‐stage programs including Cystic Fibrosis (CF), Pulmonary Arterial Hypertension (PAH), and Acute Respiratory Distress Syndrome. Alveolus Bio has offices in Birmingham, AL and Cambridge, MA

The SAFE notes investment is expected to be completed within a month of signing the definitive agreements.

shilpa medicareshilpa medicare newsalveolus bioshilpa biologicsinvestment

Ruchika Sharma

Ruchika Sharma joined Medical Dialogue as an Correspondent for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751